Recurrent Childhood Acute Lymphoblastic Leukemia Completed Phase 1 Trials for DB00293 (Raltitrexed)

IndicationStatusPhase
DBCOND0028597 (Recurrent Childhood Acute Lymphoblastic Leukemia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00003528Raltitrexed in Treating Children With Refractory Acute LeukemiaTreatment